Neuromagen Pharma
Beer Sheva, Israel· Est.
Telomerase‑activating therapeutics for neurodegeneration and systemic age‑related disorders.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Telomerase‑activating therapeutics for neurodegeneration and systemic age‑related disorders.
NeurodegenerationAlzheimer's diseaseCardiovascular agingMetabolic diseaseReproductive healthHair and skin rejuvenationAnti‑aging
Technology Platform
Small‑molecule telomerase activators (AGS compounds) that up‑regulate TERT activity to protect mitochondria, reduce oxidative stress, and stimulate stem‑cell renewal across tissues.
Opportunities
Leveraging a unified telomerase‑activation platform enables rapid expansion across high‑growth neurodegenerative, metabolic, and anti‑aging markets.
Risk Factors
Scientific validation in humans, regulatory acceptance of telomerase activation, and competition from alternative neuroprotective and rejuvenation strategies.
Competitive Landscape
Few companies target telomerase activation; Neuromagen’s differentiation lies in its multi‑tissue rejuvenation data, but it must compete with gene‑therapy and biologic approaches in neurodegeneration.